10-Jul-2026
Market Chameleon (Tue, 26-May 6:33 AM ET)
Globe Newswire (Tue, 26-May 7:15 AM ET)
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
Globe Newswire (Thu, 21-May 11:27 PM ET)
NervGen Announces Proposed Public Offering of Securities
Globe Newswire (Thu, 21-May 4:01 PM ET)
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
Globe Newswire (Mon, 18-May 7:15 AM ET)
Globe Newswire (Mon, 27-Apr 7:30 AM ET)
Globe Newswire (Mon, 13-Apr 7:45 AM ET)
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
Nervgen Pharma Corp. trades on the NASDAQ stock market under the symbol NGEN.
As of July 10, 2026, NGEN stock price climbed to $1.88 with 769,750 million shares trading.
NGEN has a beta of 1.34, meaning it tends to be more sensitive to market movements. NGEN has a correlation of 0.03 to the broad based SPY ETF.
NGEN has a market cap of $200.06 million. This is considered a Small Cap stock.
NGEN support price is $1.76 and resistance is $1.96 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NGEN shares will trade within this expected range on the day.